Related Experiment Videos
[Oncogenes and tumor promotion]
C Lafarge-Frayssinet1, C Frayssinet
1Laboratoire de pathologie cellulaire de l'UPR 278, Institut de recherches scientifiques sur le cancer, Villejuif, France.
Bulletin Du Cancer
|January 1, 1990
Summary
This study investigated how phenobarbital and biliverdin affect liver oncogene expression in rats. Both promoters significantly increased the expression of c-Ki-ras, c-fos, and c-myc oncogenes in liver cells.
Area of Science:
- Hepatology and Molecular Oncology
- Biochemistry and Cell Biology
Context:
- Investigating the role of hepatic promoters in liver oncogene expression.
- Utilizing both in vitro and in vivo models to study liver regeneration and preneoplastic nodules.
Purpose:
- To examine the impact of phenobarbital (exogenous promoter) and biliverdin (endogenous promoter) on oncogene expression in liver cells.
- To analyze the effects on c-Ki-ras, c-fos, and c-myc oncogenes, which are critical for liver growth, differentiation, and tumorigenesis.
Summary:
- Studied the effects of phenobarbital and biliverdin on c-Ki-ras, c-fos, and c-myc oncogene expression in rat liver cells.
- Experiments were conducted in vitro using liver cell strains and in vivo using regenerating liver and preneoplastic nodules.
- Observed significant overexpression of these oncogenes under the influence of both promoters.
Impact:
- Provides insights into the mechanisms of liver oncogenesis and the role of specific promoters.
- Highlights the potential involvement of phenobarbital and biliverdin in regulating genes associated with liver cancer development.
- Contributes to understanding liver cell growth, differentiation, and tumorigenesis pathways.